Study of AR-13324 in Patients With Elevated Intraocular Pressure
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
In this double-masked, vehicle-controlled, dose-response study, subjects will be randomized
to receive AR-13324 Ophthalmic Solution 0.01%, 0.02%, and 0.04% or its vehicle (one eye),
once daily (QD)in the morning (AM) for 7 days. The first dose and last dose will be
administered in the clinic. Ocular safety and ocular hypotensive efficacy will be evaluated
in the clinic throughout the study.